approval
saveELELYSO (TALIGLUCERASE ALFA) — FDA approval
community read0 votes
Sponsor: PFIZER. Form: POWDER. Route: INTRAVENOUS
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- approvalELELYSO (TALIGLUCERASE ALFA) — FDA approvalDec 22, 2025 · 286d ago
- approvalELELYSO (TALIGLUCERASE ALFA) — FDA approvalJan 17, 2025 · 625d ago
- approvalELELYSO (TALIGLUCERASE ALFA) — FDA approvalJul 10, 2024 · 816d ago
- approvalELELYSO (TALIGLUCERASE ALFA) — FDA approvalMay 9, 2023 · 1244d ago
- approvalELELYSO (TALIGLUCERASE ALFA) — FDA approvalAug 30, 2022 · 1496d ago
- approvalELELYSO (TALIGLUCERASE ALFA) — FDA approvalNov 3, 2020 · 2161d ago
- approvalELELYSO (TALIGLUCERASE ALFA) — FDA approvalDec 20, 2016 · 3575d ago
- approvalELELYSO (TALIGLUCERASE ALFA) — FDA approvalJun 15, 2016 · 3763d ago
same company · ±60 days · 6
- approvalABRILADA: ABRILADA (ADALIMUMAB-AFZB) — FDA approvalNov 15, 2019
- approvalHEPARIN SODIUM: HEPARIN SODIUM — FDA approvalSep 19, 2019
- approvalHEPARIN SODIUM: HEPARIN SODIUM — FDA approvalSep 19, 2019
- approvaltofacitinib citrate ER: XELJANZ XR (TOFACITINIB CITRATE) — FDA approvalDec 12, 2019
- approvaltofacitinib citrate ER: XELJANZ XR (TOFACITINIB CITRATE) — FDA approvalAug 30, 2019
- approvalCLEOCIN: CLEOCIN (CLINDAMYCIN PHOSPHATE) — FDA approvalDec 16, 2019
comments(0)
5-min edit window · permanent after that